Literature DB >> 32763918

Morphological control for molecular testing: a practical approach.

Irene Gullo1,2, Ana Marques1,2,3, Regina Pinto3, Luis Cirnes3, Fernando Schmitt4,3.   

Abstract

The determination of molecular aberrations within tumours is important for diagnostic, prognostic and predictive purposes. Pathologists play a critical role in the workflow of molecular diagnostics, by assuring accurate pathological diagnosis, requesting appropriate molecular testing, selecting the adequate tissue section for molecular analysis, enriching tumour cell content by manual macrodissection and estimating the tumour cellularity. Particularly, the assessment of the malignant cell fraction within a tumour section is a key determinant for an appropriate interpretation of the molecular findings. Several factors may impact the estimation of tumour cellularity and constitute a potential pitfall for the final interpretation of the molecular analysis. Evidence suggests that the reliability of morphological control could be improved by training. The scope of this commentary is to provide the training morpho-molecular pathologists with the practical tools necessary to master microscopic morphological control for solid tumours, as well as a set of images that could serve as a training set. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  morphological and microscopic findings; pathology, molecular; quality control

Year:  2020        PMID: 32763918     DOI: 10.1136/jclinpath-2020-206890

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  1 in total

Review 1.  Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management.

Authors:  Frédérique Penault-Llorca; Keith M Kerr; Pilar Garrido; Erik Thunnissen; Elisabeth Dequeker; Nicola Normanno; Simon J Patton; Jenni Fairley; Joshua Kapp; Daniëlle de Ridder; Aleš Ryška; Holger Moch
Journal:  Virchows Arch       Date:  2022-07-20       Impact factor: 4.535

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.